Abstract
Objectives:To evaluate the effects and safety of intravitreal ranibizumab on visual acuity and anatomic results in the treatment of macular edema due to retinal vein occlusion (RVO).Methods:Forty Six eyes of 45 patients who were administered intravitreal ranibizumab because of macular edema due to Retinal Vein Occlusion (RVO) were included in this retrospective clinical study. During monthly follow-up, the best corrected visual acuity values in terms of LogMAR with The Early Treatment Diabetic Retinopathy Study (ETDRS) chart, central macular thickness (CMT), and complications were examined. Cases were classified as central retinal vein occlusion (CRVO), superotemporal branch retinal vein occlusion (BRVO), and inferotemporal BRVO. We only included RVO patients but using ETDRS chart for the vision measurement.Results:In all follow-up months, there was a significant increase in BCVA in all RVO cases and in superotemporal BRVO cases after the first injection of ranibizumab. Although there was no significant increase in the 1st month of follow-up period compared to pre-treatment, there was significant increase in 2-6 months in inferotemporal BRVO patients. There was no statistically significant increase in 1st and 2nd month follow-up periods compared to pre-treatment; however there was a significant increase in 3-6 months in the CRVO patients. There was a significant decrease in average CMT measurements in all follow-up months compared to pre-treatment in all RVO cases, in superotemporal and inferotemporal BRVO cases. There was no significant decrease in average CMT measurements in the 1st, 2nd, and 3rd months compared to pre-treatment although there was a significant decrease in 4-6 months in cases included in the CRVO patients.Conclusions:Intraocular ranibizumab injections provided rapid, effective treatment for macular edema due to RVO with low rates of ocular and nonocular safety events. However, repeated injections and frequent follow-up intervals may be required.
Highlights
Macular edema, a leading cause of vision loss, has been reported in 60% of cases of retinal vein occlusion (RVO).1 The use of grid laser photocoagulation is known to be an effective treatment option in treatment of macular edema due to branch retinal vein occlusion (BRVO).2 grid laser photocoagulation has limited application due to the risk of developing iatrogenic paracentral scotoma; in addition, some eyes are resistant to treatment.3 In addition grid laser photocoagulation treatment has not been recommended in macular edema due to central retinal vein occlusion (CRVO).4Ischemia that develops as a result of vascular occlusion causes the release of vascular endothelial growth factor (VEGF) from the retina and disruption of the blood retinal barrier.5 VEGF contribute to the development of macular edema
In addition grid laser photocoagulation treatment has not been recommended in macular edema due to CRVO.4
Medical records of 46 eyes of 45 patients who had macular edema due to CRVO, superotemporal and inferotemporal branch retinal vein occlusion (BRVO), who were injected with intravitreal ranibizumab were studied retrospectively between
Summary
A leading cause of vision loss, has been reported in 60% of cases of retinal vein occlusion (RVO). The use of grid laser photocoagulation is known to be an effective treatment option in treatment of macular edema due to branch retinal vein occlusion (BRVO). grid laser photocoagulation has limited application due to the risk of developing iatrogenic paracentral scotoma; in addition, some eyes are resistant to treatment. In addition grid laser photocoagulation treatment has not been recommended in macular edema due to CRVO.4Ischemia that develops as a result of vascular occlusion causes the release of vascular endothelial growth factor (VEGF) from the retina and disruption of the blood retinal barrier. VEGF contribute to the development of macular edema. A leading cause of vision loss, has been reported in 60% of cases of retinal vein occlusion (RVO).. The use of grid laser photocoagulation is known to be an effective treatment option in treatment of macular edema due to branch retinal vein occlusion (BRVO).. Grid laser photocoagulation has limited application due to the risk of developing iatrogenic paracentral scotoma; in addition, some eyes are resistant to treatment.. In addition grid laser photocoagulation treatment has not been recommended in macular edema due to CRVO.. Ischemia that develops as a result of vascular occlusion causes the release of vascular endothelial growth factor (VEGF) from the retina and disruption of the blood retinal barrier.. VEGF contribute to the development of macular edema. VEGF has proinflammatory properties and there are VEGF receptors on inflammatory cells.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
